These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26257301)

  • 1. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
    Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
    Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
    Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
    Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
    Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
    Chuang TD; Chen SJ; Lin FF; Veeramani S; Kumar S; Batra SK; Tu Y; Lin MF
    J Biol Chem; 2010 Jul; 285(31):23598-606. PubMed ID: 20498373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
    Lee MS; Igawa T; Yuan TC; Zhang XQ; Lin FF; Lin MF
    Oncogene; 2003 Feb; 22(5):781-96. PubMed ID: 12569372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of protein S in castration-resistant prostate cancer-like cells.
    Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
    Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
    Lin HP; Ho HM; Chang CW; Yeh SD; Su YW; Tan TH; Lin WJ
    FASEB J; 2019 Dec; 33(12):14653-14667. PubMed ID: 31693867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
    Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
    Cai C; Portnoy DC; Wang H; Jiang X; Chen S; Balk SP
    Cancer Res; 2009 Jun; 69(12):5202-9. PubMed ID: 19491261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
    Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
    Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
    Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS
    Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
    Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling.
    Hu J; Zhu W; Wei B; Wen H; Mao S; Xu H; Hu M; Yang T; Jiang H
    Anticancer Drugs; 2016 Nov; 27(10):944-52. PubMed ID: 27537398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.